Damage-associated molecular patterns (DAMPS) in patients with advanced cancer undergoing systemic treatment.

• DOI: 10.1200/jco.2022.40.16_suppl.e14524
• Publication Date: 2022-06-06T16:07:43Z
• Authors: Vicente Valenti; Laia Capdevila; Isabel Ruiz; Joan Badia; Francisco Javier ...; Susana Blázquez; Óscar Villuendas; Cristina Pérez; Gemma Flores; Mónica Córdoba; Carlos Alonso
• Keywords: Carboplatin; Panitumumab; Pertuzumab; Pemetrexed

e14524 Background: Immunogenic cell death (ICD) is known for the release of DAMPS from tumor cells. We aimed to find signals ICD by assessing variation plasma (HMGB1 and S100A8) after vs. before standard care (SoC) systemic treatment in patients with advanced solid tumors. Methods: Patients scheduled start a new line were included. Plasma concentrations HMGB1 S100A8 measured (ng/mL) three months treatment. CD44 immunohistochemical (IHC) expression was determined tissue. After paired median analyzed Wilcoxon signed-rank test whole population selected subgroups according RECIST response, baseline plasmatic iron levels, expression, platinum-based Results: Fifty-two The most frequent sites colorectal (35%) lung (25%). Forty-two (81%) received this as first-line. Thirty-six (69%) chemotherapy (CT) alone, ten (19%) CT plus targeted therapy (7 FOLFOX or XELOX bevacizumab, one each cetuximab, panitumumab, docetaxel-trastuzumab-pertuzumab), two (3.8%) carboplatin-pemetrexed-pembrolizumab, (5.8%) pembrolizumab alone (1.9%) cetuximab alone. Overall response rate (RECIST) 42%, low levels 53%, positive 35% patients. Results on concentration are shown table. Conclusions: Signals not observed these significant while significantly decreased treatment, more markedly those who experienced response.[Table: see text]